Skip to content

A prospective, multicenter, randomized controlled study on the comparison of the efficacy of three reconstruction surgeries (Kamikawa, double tract reconstruction and tube-like stomach) after proximal gastrectomy

A prospective, multicenter, randomized controlled study on the comparison of the efficacy of three reconstruction surgeries (Kamikawa, double tract reconstruction and tube-like stomach) after proximal gastrectomy

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100045975
Enrollment
Unknown
Registered
2021-04-30
Start date
2021-05-01
Completion date
Unknown
Last updated
2021-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Proximal gastric cancer

Interventions

Group A :Kamikawa anastomosis
Group B :double-tract reconstruction
Group C :tube-like stomach

Sponsors

The First Affiliated Hospital of Air Force Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 20 to 75 years, both males and females; 2. Preoperative endoscopic biopsy pathological diagnosis: the tumor is located in the upper 1/3 of the stomach (including the esophagogastric junction). According to the eighth edition of AJCC, the clinical staging of gastric cancer is Ia and Ib (T1N0M0, T1N1 M0 and T2N0 M0); 3. No distant metastasis was found on chest radiograph, abdominal ultrasound, and CT of the upper abdomen before operation; 4. ASA classification 1-3; 5. The patient and his family voluntarily participated in the study and signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1. The patient has coagulation dysfunction and cannot be corrected; 2. Patients with viral hepatitis and liver cirrhosis; 3. Patients with metabolic diseases such as diabetes; 4. Patients with failure of important organs such as heart, lung, liver, brain, and kidney; 5. Acute infection, especially patients with biliary tract infection; 6. The patient has a mental disorder or disorder of consciousness; 7. Patients with immunodeficiency, immunosuppression or autoimmune diseases (such as patients undergoing allogeneic bone marrow transplantation within the past five years, taking immunosuppressive drugs, SLE, etc.).

Design outcomes

Primary

MeasureTime frame
Incidence of reflux esophagitis;

Secondary

MeasureTime frame
Incidence of anastomotic leakage;Incidence of anastomotic stenosis;operative time;intraoperative blood loss;

Countries

China

Contacts

Public ContactJi Gang

The First Affiliated Hospital of Air Force Medical University

jigang@fmmu.com+86 13572152581

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026